Pure Financial Advisors
CLDI icon

Pure Financial Advisors’s Calidi Biotherapeutics CLDI Stock Holding History

Pure Financial Advisors’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6
Closed -$6.72K – 316
2024
Q1 		$6.72K Hold
6
– – ﹤0.01% 313
2023
Q4 		$18K Buy
+6
New +$25.8K ﹤0.01% 302

Other funds holding CLDI

Red Wave Investments
Red Wave Investments Dillsburg, Pennsylvania $408M AUM 17.01% 1-Year Est. Return
CPR Investments
CPR Investments Rochester, Michigan $134M AUM 22.6% 1-Year Est. Return
RS Crum Inc
RS Crum Inc Newport Beach, California $534M AUM 14.22% 1-Year Est. Return
Delta Investment Management
Delta Investment Management San Francisco, California $619M AUM 18.05% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Finepoint Capital
Finepoint Capital Boston, Massachusetts $2.8B AUM 13.35% 1-Year Est. Return
HRT Financial
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Highbridge Capital Management
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Pure Financial Advisors's CLDI Position: Q2 2024 in Review

Pure Financial Advisors sold out of Calidi Biotherapeutics (CLDI) in Q2 2024, closing a stake of 6 shares — an estimated $6.72K sold.

Pure Financial Advisors first reported a position in CLDI in Q4 2023 and held it in 2 quarters. The position peaked at $18K in Q4 2023. 29 funds tracked by Wall St. Rank hold CLDI as of Q2 2024.

  • Pure Financial Advisors reported no remaining Calidi Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Pure Financial Advisors sold 6 Calidi Biotherapeutics shares in Q2 2024, an estimated $6.72K.
  • Pure Financial Advisors first reported a position in Calidi Biotherapeutics in Q4 2023 and held it in 2 quarters.
  • Pure Financial Advisors's Calidi Biotherapeutics position peaked at $18K in Q4 2023.
  • 29 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2024.

Based on Pure Financial Advisors's 13F filing for Q2 2024, filed 18 Jul 2024.